ARS Pharmaceuticals, Inc. (SPRY) income statement
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.69+0.04 (+1.10%)
Close on Nov 18, 2026Market cap $366.96MP/E –Yield –
ARS Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -185.0%
- Net margin
- -184.2%
- Return on equity, FY2025
- -92.3%
Financial strength
- Current ratio
- 3.48
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 13.4%
Valuation
- P/E ratio
- –
- Price to sales
- 3.14
- Price to book
- 29.33
- Dividend yield
- –
See a number that looks wrong?